Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized pharmacokinetic study of standard versus extended-interval nivolumab or pembrolizumab dosing in advanced or metastatic cancer
MOH_2020-12-13_009514Phase 4Not yet recruiting
- Sponsor
- Mark J. Ratain
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nivolumab and pembrolizumab in cancer (2 arms), sponsored by Mark J. Ratain. Primary endpoint: Pharmacokinetic non-inferiority based on trough concentration. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on MOH_2020-12-13_009514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-13_009514.